DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Up 6.8 %

NASDAQ:DBVT opened at $5.21 on Friday. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $8.46. The business has a 50 day moving average price of $4.34 and a two-hundred day moving average price of $3.82. The company has a market cap of $107.16 million, a P/E ratio of -1.16 and a beta of 0.71.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.